J. Brent Muhlestein

J. Brent Muhlestein, MD

Languages spoken: English, Korean

Academic Information

Departments Primary - Internal Medicine

Divisions: Cardiovascular Medicine

Board Certification

  • American Board of Internal Medicine (Internal Medicine)
  • American Board of Internal Medicine (Sub: Cardiovascular Disease)
  • American Board of Internal Medicine (Sub: Interventional Cardiology)
  • National Board of Medical Examiners

A. 1993-2002 Medical Director of LDS Hospital Medical Records Committee.
B. 1992-1997 Member LDS Hospital Medicine Quality Control Committee.
C. 1994-2005 Director of IHC Salt Lake Valley Continuing Medical Education Committee,
an ACCME accredited body.
D. 1995-2005 Medical Director IHC PTCA Care Process Model Development and
Implementation Team.
E. 1995-1998 Member, Utah Medical Assistance Program, Drug Utilization Review Board
F. 1995-2005 Medical Director IHC Heart Services, Clinical Data Management Group.
G. 1996-present Member, Deseret Foundation, Research and Awards Committee
H. 1996-2005 Member, LDS Hospital Radiation Safety Committee.
I. 1997-2007 Co-Director of LDS Hospital Cardiac Catheterization Laboratory.
J. 1997-present Member, American Heart Association, Research and Awards Committee,
Western Division
K. 1998-1999 Member, LDS Hospital, House Staff Executive Committee
L. 1999-2010 Director of Cardiology Research for Intermountain Health Care.
M. 2010-present Co-Director of Cardiology Rsearch for Intermountain Health Care
N. 2007-present Director of Interventional Cardiology Training Program at IMC
O. 2009-2010 Chairman of Deseret Foundation Research and Scientific Awards Review
Committee, IMC
P 2012-Present Participation on the U of U PhD Committee for Senthil K. Nachimuthu, MD

Education History

Fellowship Duke University Medical Center
 Fellow
Residency Duke University Medical Center
 Resident
Internship Duke University Medical Center
 Intern
Professional Medical University of Utah Hospital School of Medicine
 MD
Undergraduate Brigham Young University
 BS

Selected Publications

Journal Article

  1. May HT, Le VT, Anderson JL, Iverson L, Bair TL, Knight S, Knowlton KU, Peterson BE, Muhlestein JB (2026). Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial. Eur Heart J.
  2. Anderson JL, May HT, Winslow T, Le VT, Iverson L, Bair TL, Knowlton KU, Muhlestein JB (2026). CorCal Outcomes: A randomized trial using the pooled cohort equation or coronary artery calcium to select statin therapy in primary prevention patients. Study design and baseline characteristics. Am Heart J, 299, 107473.
  3. Bunch TJ, May HT, Muhlestein JB, Anderson JL, Le V, Woller SC, Cutler MJ, Mahajan R, Targueta GP, Gurol ME, Knowlton K (2026). Concussion AF trial: Longitudinal assessment of brain injury biomarkers and cognitive decline in elderly patients with atrial fibrillation. Heart Rhythm.
  4. Knowlton KU, Navar AM, Anderson JL, Brown AS, Muhlestein JB, Kleeman K, Sarwat S, Abbas CA, Ramirez MA, Grines CL, Abo-Auda WS, Desai NR (2026). Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. J Am Heart Assoc, 15(10), e043655.
  5. Anderson JL, Collingridge DS, Le VT, Iverson L, Muhlestein JB, Bair TL, Knight S, Mason SM, Knowlton KU (2025). Does Sex or Age Impact the Prognostic Value of a Zero Coronary Artery Calcium Score? J Clin Med, 14(17).
  6. Bunch KT, May HT, Knowlton KU, Bair TL, Muhlestein JB, Anderson JL, Ranjan R, Steinberg BA, Bunch TJ (2025). Atrial Fibrillation as a Predictor of Age-Related Macular Degeneration. J Cardiovasc Electrophysiol, 36(5), 990-995.
  7. May HT, Anderson JL, Butzner M, Divanji PH, Muhlestein JB (2024). Clinicoeconomic burden among heart failure patients with severely reduced ejection fraction after hospital admission: HF-RESTORE. Eur Heart J Qual Care Clin Outcomes, 11(2), 149-159.
  8. Horne BD, Anderson JL, May HT, Bair TL, Le VT, Iverson L, Knowlton KU, Muhlestein JB (2025). Weight loss-independent changes in human growth hormone during water-only fasting: a secondary evaluation of a randomized controlled trial. Front Endocrinol (Lausanne), 15, 1401780.
  9. Horne BD, Anderson JL, May HT, Bair TL, Le VT, Iverson L, Knowlton KU, Muhlestein JB (2024). Insulin resistance reduction, intermittent fasting, and human growth hormone: secondary analysis of a randomized trial. NPJ Metab Health Dis, 2(1), 26.
  10. Koppold DA, Breinlinger C, Hanslian E, Kessler C, Cramer H, Khokhar AR, Peterson CM, Tinsley G, Vernieri C, Bloomer RJ, Boschmann M, Bragazzi NL, Brandhorst S, Gabel K, Goldhamer AC, Grajower MM, Harvie M, Heilbronn L, Horne BD, Karras SN, Langhorst J, Lischka E, Madeo F, Mitchell SJ, Papagiannopoulos-Vatopaidinos IE, Papagiannopoulou M, Pijl H, Ravussin E, Ritzmann-Widderich M, Varady K, Adamidou L, Chihaoui M, de Cabo R, Hassanein M, Lessan N, Longo V, Manoogian ENC, Mattson MP, Muhlestein JB, Panda S, Papadopoulou SK, Rodopaios NE, Stange R, Michalsen A (2024). International consensus on fasting terminology. Cell Metab, 36(8), 1779-1794.e4.
  11. Horne BD, Atreja N, Venditto J, Wilson T, Muhlestein JB, St Clair JR, Knowlton KU, Khan ND, Bhalla N, Anderson JL (2024). Contemporary Predictors of Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention: A Nationally Representative US Sample. J Clin Med, 13(10).
  12. Anderson JL, Knowlton KU, May HT, Le VT, Lappe DL, Cripps ST, Schwab LH, Winslow T, Bair TL, Muhlestein JB (2023). Impact of Active vs Passive Statin Selection for Primary Prevention: The CorCal Vanguard Trial. JACC Adv, 2(10), 100676.
  13. Horne BD, Anderson JL, May HT, Le VT, Bair TL, Bennett ST, Knowlton KU, Muhlestein JB (2023). Intermittent fasting and changes in clinical risk scores: Secondary analysis of a randomized controlled trial. Int J Cardiol Cardiovasc Risk Prev, 19, 200209.
  14. Le VT, Knight S, Watrous JD, Najhawan M, Dao K, McCubrey RO, Bair TL, Horne BD, May HT, Muhlestein JB, Nelson JR, Carlquist JF, Knowlton KU, Jain M, Anderson JL (2023). Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events. Front Cardiovasc Med, 10, 1229130.
  15. Buckler AJ, Doros G, Kinninger A, Lakshmanan S, Le VT, Libby P, May HT, Muhlestein JB, Nelson JR, Nicolaou A, Roy SK, Shaikh K, Shekar C, Tayek JA, Zheng L, Bhatt DL, Budoff MJ (2023). Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE. Front Cardiovasc Med, 10, 1204071.
  16. Anderson JL, May HT, Le VT, Muhlestein JB, Horne BD, Bair TL, Knight S, Knowlton KU (2023). Impact of Statin Therapy in Heart Failure Patients: Results of a Large Real-World Experience. JACC Adv, 2(4), 100385.
  17. Anderson JL, Knight S, May HT, Le VT, Bair TL, Knowlton KU, Muhlestein JB (2023). Frequency and Outcomes of Patients Presenting with Non-ST Elevation Myocardial Infarction (NSTEMI) without Standard Modifiable Risk Factors: A US Healthcare Experience. J Clin Med, 12(9).
  18. Weinstock JS, Gopakumar J, Burugula BB, Uddin MM, Jahn N, Belk JA, Bouzid H, Daniel B, Miao Z, Ly N, Mack TM, Luna SE, Prothro KP, Mitchell SR, Laurie CA, Broome JG, Taylor KD, Guo X, Sinner MF, von Falkenhausen AS, Kb S, Shuldiner AR, OConnell JR, Lewis JP, Boerwinkle E, Barnes KC, Chami N, Kenny EE, Loos RJF, Fornage M, Hou L, Lloyd-Jones DM, Redline S, Cade BE, Psaty BM, Bis JC, Brody JA, Silverman EK, Yun JH, Qiao D, Palmer ND, Freedman BI, Bowden DW, Cho MH, DeMeo DL, Vasan RS, Yanek LR, Becker LC, Kardia SLR, Peyser PA, He J, Rienstra M, Van der Harst P, Kaplan R, Heckbert SR, Smith NL, Wiggins KL, Arnett DK, Irvin MR, Tiwari H, Cutler MJ, Knight S, Muhlestein JB, Correa A, Raffield LM, Gao Y, de Andrade M, Rotter JI, Rich SS, Tracy RP, Konkle BA, Johnsen JM, Wheeler MM, Smith JG, Melander O, Nilsson PM, Custer BS, Duggirala R, Curran JE, Blangero J, McGarvey S, Williams LK, Xiao S, Yang M, Gu CC, Chen YI, Lee WJ, Marcus GM, Kane JP, Pullinger CR, Shoemaker MB, Darbar D, Roden DM, Albert C, Kooperberg C, Zhou Y, Manson JE, Desai P, Johnson AD, Mathias RA, NHLBI Trans-Omics for Precision Medicine TOPMed Consortium, Blackwell TW, Abecasis GR, Smith AV, Kang HM, Satpathy AT, Natarajan P, Kitzman JO, Whitsel EA, Reiner AP, Bick AG, Jaiswal S (2023). Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. Nature, 616(7958), 755-763.
  19. Otvos JD, Shalaurova I, May HT, Muhlestein JB, Wilkins JT, McGarrah RW 3rd, Kraus WE (2022). Multimarkers of metabolic malnutrition and inflammation and their association with mortality risk in cardiac catheterisation patients: a prospective, longitudinal, observational, cohort study. Lancet Healthy Longev, 4(2), e72-e82.
  20. Anderson JL, Knight S, May HT, Le VT, Almajed J, Bair TL, Knowlton KU, Muhlestein JB (2022). Cardiovascular Outcomes of ST-Elevation Myocardial Infarction (STEMI) Patients without Standard Modifiable Risk Factors (SMuRF-Less): The Intermountain Healthcare Experience. J Clin Med, 12(1).
  21. Cutler MJ, May HT, Bair TL, Crandall BG, Osborn JS, Miller JD, Mallender CD, Muhlestein JB, Anderson JL, Knowlton KU, Knight S (2022). Atrial fibrillation is a risk factor for major adverse cardiovascular events in COVID-19. Int J Cardiol Heart Vasc, 43, 101127.
  22. Bunch TJ, May H, Cutler M, Woller SC, Jacobs V, Stevens SM, Carlquist J, Knowlton KU, Muhlestein JB, Steinberg BA, Anderson JL (2022). Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (cognitive decline and dementia in patients with non-valvular atrial fibrillation [CAF] trial). J Arrhythm, 38(6), 997-1008.
  23. Anderson JL, Le VT, Bair TL, Muhlestein JB, Knowlton KU, Horne BD (2022). Is Alcohol Consumption Associated with a Lower Risk of Cardiovascular Events in Patients Treated with Statins? An Observational Real-World Experience. J Clin Med, 11(16).
  24. Muhlestein JB, Dranow E, Chaney J, Navaravong L, Steinberg BA, Freedman RA (2022). Successful avoidance of superior vena cava injury during transvenous lead extraction using a tandem femoral-superior approach. Heart Rhythm, 19(7), 1104-1108.
  25. Horne BD, May HT, Muhlestein JB, Le VT, Bair TL, Knowlton KU, Anderson JL (2022). Association of periodic fasting with lower severity of COVID-19 outcomes in the SARS-CoV-2 prevaccine era: an observational cohort from the INSPIRE registry. BMJ Nutr Prev Health, 5(2), 145-153.
  26. Anderson JL, Horne BD, Le VT, Bair TL, Min DB, Minder CM, Dhar R, Mason S, Muhlestein JB, Knowlton KU (2020). Spectrum of radionuclide perfusion study abnormalities in takotsubo cardiomyopathy. J Nucl Cardiol, 29(3), 1034-1046.
  27. Haddad F, Ataam JA, Amsallem M, Cauwenberghs N, Kuznetsova T, Rosenberg-Hasson Y, Zamanian RT, Karakikes I, Horne BD, Muhlestein JB, Kwee L, Shah S, Maecker H, Knight S, Knowlton K (2021). Insulin Growth Factor Phenotypes in Heart Failure With Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study. J Card Fail, 28(6), 935-946.
  28. Horne BD, Anderson JL, May HT, Le VT, Galenko O, Drakos SG, Bair TL, Knowlton KU, Muhlestein JB (2022). Intermittent fasting and changes in Galectin-3: A secondary analysis of a randomized controlled trial of disease-free subjects. Nutr Metab Cardiovasc Dis, 32(6), 1538-1548.
  29. Drozda JP Jr, Graham J, Muhlestein JB, Tcheng JE, Roach J, Forsyth T, Knight S, McKinnon A, May H, Wilson NA, Berlin JA, Simard EP (2022). Multi-institutional distributed data networks for real-world evidence about medical devices: building unique device identifiers into longitudinal data (BUILD). JAMIA Open, 5(2), ooac035.
  30. May HT, Knowlton KU, Anderson JL, Lapp DL, Bair TL, Muhlestein JB (2021). High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: results from the IMPRES study. Eur Heart J Qual Care Clin Outcomes, 8(3), 352-360.
  31. Kurella Tamura M, Gaussoin S, Pajewski NM, Zaharchuk G, Freedman BI, Rapp SR, Auchus AP, Haley WE, Oparil S, Kendrick J, Roumie CL, Beddhu S, Cheung AK, Williamson JD, Detre JA, Dolui S, Bryan RN, Nasrallah IM, SPRINT Research Group (2021). Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure. Am J Kidney Dis, 79(5), 677-687.e1.
  32. Muhlestein JB, Knowlton KU, Le VT, Lappe DL, May HT, Min DB, Johnson KM, Cripps ST, Schwab LH, Braun SB, Bair TL, Anderson JL (2021). Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial. JACC Cardiovasc Imaging, 15(5), 843-855.
  33. Roselli C, Yu M, Nauffal V, Georges A, Yang Q, Love K, Weng LC, Delling FN, Maurya SR, Schrlkamp M, Tfelt-Hansen J, Hagge A, Jeunemaitre X, Debette S, Amouyel P, Guan W, Muehlschlegel JD, Body SC, Shah S, Samad Z, Kyryachenko S, Haynes C, Rienstra M, Le Tourneau T, Probst V, Roussel R, Wijdh-Den Hamer IJ, Siland JE, Knowlton KU, Jacques Schott J, Levine RA, Benjamin EJ, Vasan RS, Horne BD, Muhlestein JB, Benfari G, Enriquez-Sarano M, Natale A, Mohanty S, Trivedi C, Shoemaker MB, Yoneda ZT, Wells QS, Baker MT, Farber-Eger E, Michelena HI, Lundby A, Norris RA, Slaugenhaupt SA, Dina C, Lubitz SA, Bouatia-Naji N, Ellinor PT, Milan DJ (2021). Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. Eur Heart J, 43(17), 1668-1680.
  34. Muhlestein JB, Kammerer J, Bair TL, Knowlton KU, Le VT, Anderson JL, Lapp DL, May HT (2022). Real-world clinical burden and economic assessment associated with hyperkalaemia in a large integrated healthcare system: a retrospective analysis. BMC Prim Care, 23(1), 65.
  35. Horne BD, Bledsoe JR, Muhlestein JB, May HT, Peltan ID, Webb BJ, Carlquist JF, Bennett ST, Rea S, Bair TL, Grissom CK, Knight S, Ronnow BS, Le VT, Stenehjem E, Woller SC, Knowlton KU, Anderson JL (2022). Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort. BMJ Open, 12(3), e053864.
  36. Horne BD, Muhlestein JB, Lapp DL, May HT, Le VT, Bair TL, Babcock D, Bride D, Knowlton KU, Anderson JL (2021). Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial. Am Heart J, 244, 125-134.
  37. Bartholomew CL, Muhlestein JB, Anderson JL, May HT, Knowlton KU, Bair TL, Le VT, Bailey BW, Horne BD (2020). Association of periodic fasting lifestyles with survival and incident major adverse cardiovascular events in patients undergoing cardiac catheterization. Eur J Prev Cardiol, 28(16), 1774-1781.
  38. Burnham TS, May HT, Bair TL, Anderson JA, Crandall BG, Cutler MJ, Day JD, Freedman RA, Knowlton KU, Muhlestein JB, Navaravong L, Ranjan RA, Steinberg BA, Bunch TJ (2021). Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease. Am Heart J, 243, 127-139.
  39. Knowlton KU, Knight S, Muhlestein JB, Le VT, Horne BD, May HT, Stenehjem EA, Anderson JL (2021). A Small but Significantly Greater Incidence of Inflammatory Heart Disease Identified After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infect Dis, 9(3), ofab663.
  40. Horne BD, Muhlestein JB, May HT, Le VT, Bair TL, Bennett ST, Knowlton KU, Anderson JL (2021). Preferential Metabolic Improvement by Intermittent Fasting in People with Elevated Baseline Red Cell Distribution Width: A Secondary Analysis of the WONDERFUL Randomized Controlled Trial. Nutrients, 13(12).
  41. Anderson JL, Knight S, McCubrey RO, May HT, Mason S, Bunch TJ, Min DB, Cutler MJ, Le VT, Muhlestein JB, Knowlton KU (2021). Absent or Mild Coronary Calcium Predicts Low-Risk Stress Test Results and Outcomes in Patients Considered for Flecainide Therapy. J Cardiovasc Pharmacol Ther, 26(6), 648-655.
  42. Skuladottir AT, Bjornsdottir G, Nawaz MS, Petersen H, Rognvaldsson S, Moore KHS, Olafsson PI, Magnusson SH, Bjornsdottir A, Sveinsson OA, Sigurdardottir GR, Saevarsdottir S, Ivarsdottir EV, Stefansdottir L, Gunnarsson B, Muhlestein JB, Knowlton KU, Jones DA, Nadauld LD, Hartmann AM, Rujescu D, Strupp M, Walters GB, Thorgeirsson TE, Jonsdottir I, Holm H, Thorleifsson G, Gudbjartsson DF, Sulem P, Stefansson H, Stefansson K (2021). A genome-wide meta-analysis uncovers six sequence variants conferring risk of vertigo. Commun Biol, 4(1), 1148.
  43. Bartholomew CL, Muhlestein JB, May HT, Le VT, Galenko O, Garrett KD, Brunker C, Hopkins RO, Carlquist JF, Knowlton KU, Anderson JL, Bailey BW, Horne BD (2021). Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial. Eur Heart J Open, 1(2), oeab026.
  44. Money JE, Muhlestein JB, Mason S, Bair TL, Knowlton KU, Horne BD, Anderson JL (2021). Simplifying the ISCHEMIA trial algorithm for clinical practice: Identifying left main coronary artery disease using coronary artery calcium scans. Am Heart J, 239, 129-134.
  45. Rizzi SA, Knight S, May HT, Woller SC, Stevens SM, Steinberg BA, Bair TL, Anderson JL, Muhlestein JB, Knowlton KU, Bunch TJ (2021). Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. Am J Cardiol, 153, 58-64.
  46. Greenland P, Michos ED, Redmond N, Fine LJ, Alexander KP, Ambrosius WT, Bibbins-Domingo K, Blaha MJ, Blankstein R, Fortmann SP, Khera A, Lloyd-Jones DM, Maron DJ, Min JK, Muhlestein JB, Nasir K, Sterling MR, Thanassoulis G (2020). Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop. JACC Cardiovasc Imaging, 14(7), 1454-1465.
  47. Anderson JL, Knowlton KU, Muhlestein JB, Bair TL, Le VT, Horne BD (2021). Evaluation of TReatment With Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer: ERACER-An Observational Cohort Study. J Cardiovasc Pharmacol Ther, 26(4), 321-327.
  48. SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius WT (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 384(20), 1921-1930.
  49. Anderson JL, May HT, Knight S, Bair TL, Muhlestein JB, Knowlton KU, Horne BD (2021). Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population. JAMA Netw Open, 4(4), e217429.
  50. Muhlestein JB, Kammerer J, Bair TL, Knowlton KU, Le VT, Anderson JL, Lapp DL, May HT (2020). Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population. ESC Heart Fail, 8(1), 691-696.
  51. Barker T, May HT, Doty JR, Lappe DL, Knowlton KU, Carlquist J, Konery K, Inglet S, Chisum B, Galenko O, Anderson JL, Muhlestein JB (2020). Vitamin D supplementation protects against reductions in plasma 25-hydroxyvitamin D induced by open-heart surgery: Assess-d trial. Physiol Rep, 9(3), e14747.
  52. Anderson JL, Christensen GB, Escobar H, Horne BD, Knight S, Jacobs V, Afshar K, Hebl VB, Muhlestein JB, Knowlton KU, Carlquist JF, Nadauld LD (2020). Discovery of TITIN Gene Truncating Variant Mutations and 5-Year Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. Am J Cardiol, 137, 97-102.
  53. May HT, Anderson JL, Muhlestein JB, Knowlton KU, Horne BD (2020). Intermountain chronic disease risk score (ICHRON) validation for prediction of incident chronic disease diagnoses in an australian primary prevention population. Eur J Intern Med, 79, 81-87.
  54. Muhlestein JB, Muhlestein JB, Anderson JL, Bethea CF, Severance HW, Mentz RJ, Barsness GW, Barbagelata A, Albert D, Le VT, Bunch TJ, Yanowitz F, May HT, Chisum B, Ronnow BS, Duke University Cooperative Cardiovascular Society DUCCS investigators (2020). Smartphone 12-lead ECG-Exciting but must be handled with care. Am Heart J, 226, 269.
  55. Alvarez Villela M, Wever-Pinzon O, Parikh M, Deru K, Muhlestein JB, Anderson JL, Weaver LK (2020). Patterns of cardiac dysfunction after carbon monoxide poisoning. Undersea Hyperb Med, 47(3), 477-485.
  56. Chandrasekhar J, Baber U, Sartori S, Aquino M, Moalem K, Kini AS, Rao SV, Weintraub W, Henry TD, Vogel B, Ge Z, Muhlestein JB, Weiss S, Strauss C, Toma C, DeFranco A, Claessen BE, Keller S, Baker BA, Effron MB, Pocock S, Dangas G, Kapadia S, Mehran R (2020). Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clin Res Cardiol, 109(6), 725-734.
  57. Bair TL, May HT, Knowlton KU, Anderson JL, Lappe DL, Muhlestein JB (2020). Predictors of Statin Intolerance in Patients With a New Diagnosis of Atherosclerotic Cardiovascular Disease Within a Large Integrated Health Care Institution: The IMPRES Study. J Cardiovasc Pharmacol, 75(5), 426-431.
  58. Chandiramani R, Chen H, Aoi S, Giustino G, Claessen B, Sartori S, Aquino M, Sorrentino S, Cao D, Goel R, Kini A, Rao S, Weintraub W, Henry TD, Kapadia S, DeFranco A, Muhlestein JB, Toma C, Effron MB, Keller S, Baker BA, Pocock S, Baber U, Mehran R (2019). Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheter Cardiovasc Interv, 95(5), 885-892.
  59. Muhlestein JB, Anderson JL, Bethea CF, Severance HW, Mentz RJ, Barsness GW, Barbagelata A, Albert D, Le VT, Bunch TJ, Yanowitz F, May HT, Chisum B, Ronnow BS, Muhlestein JB, Duke University Cooperative Cardiovascular Society DUCCS investigators (2019). Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction. Am Heart J, 221, 125-135.
  60. Anderson JL, Le VT, Min DB, Biswas S, Minder CM, McCubrey RO, Knight S, Horne BD, Mason S, Lappe DL, Muhlestein JB, Knowlton KU (2019). Comparison of Three Atherosclerotic Cardiovascular Disease Risk Scores With and Without Coronary Calcium for Predicting Revascularization and Major Adverse Coronary Events in Symptomatic Patients Undergoing Positron Emission Tomography-Stress Testing. Am J Cardiol, 125(3), 341-348.
  61. Anderson JL, Jacobs V, May HT, Bair TL, Benowitz BA, Lappe DL, Muhlestein JB, Knowlton KU, Bunch TJ (2019). Free thyroxine within the normal reference range predicts risk of atrial fibrillation. J Cardiovasc Electrophysiol, 31(1), 18-29.
  62. Le VT, Knight S, Min DB, McCubrey RO, Horne BD, Jensen KR, Meredith KG, Mason SM, Lapp DL, Anderson JL, Muhlestein JB, Knowlton KU (2020). Absence of Coronary Artery Calcium During Positron Emission Tomography Stress Testing in Patients Without Known Coronary Artery Disease Identifies Individuals With Very Low Risk of Cardiac Events. Circ Cardiovasc Imaging, 13(1), e009907.
  63. Galenko O, Jacobs V, Knight S, Bride D, Cutler MJ, Muhlestein JB, Carlquist JL, Anderson JL, Knowlton KU, Jared Bunch T (2019). Circulating Levels of Biomarkers of Cerebral Injury in Patients with Atrial Fibrillation. Am J Cardiol, 124(11), 1697-1700.
  64. Galenko O, Jacobs V, Knight S, Taylor M, Cutler MJ, Muhlestein JB, Carlquist JL, Knowlton KU, Jared Bunch T (2019). The role of microRNAs in the development, regulation, and treatment of atrial fibrillation. J Interv Card Electrophysiol, 55(3), 297-305.
  65. May HT, Lapp DL, Knowlton KU, Muhlestein JB, Anderson JL, Horne BD (2018). Prediction of Long-Term Incidence of Chronic Cardiovascular and Cardiopulmonary Diseases in Primary Care Patients for Population Health Monitoring: The Intermountain Chronic Disease Model (ICHRON). Mayo Clin Proc, 94(7), 1221-1230.
  66. Muhlestein JB, Hackett IS, May HT, Bair TL, Le VT, Anderson JL, Whisenant B, Knowlton KU, Lapp DL (2019). Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Intermountain Heart Institute STAIR Observational Registry). Am J Cardiol, 123(12), 1927-1934.
  67. May HT, Muhlestein JB, Ma Y, Lpez JAG, Coll B, Nelson J (2019). Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies. Cardiol Ther, 8(1), 91-102.
  68. Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, kerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloui H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dub MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjrvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engstrm T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots ML, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagstrm E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Khnen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Pare G, Horne BD, Mrz W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW (2019). Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circ Cardiovasc Genet, 12(4), e002470.
  69. Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, kerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dub MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjrvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagstrm E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Khnen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J, CARDIoGRAMPlusC4D Consortium, Van der Harst P, Tardif JC, Sattar N, Lang CC, Pare G, Brophy JM, Anderson JL, Mrz W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW (2019). Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circ Cardiovasc Genet, 12(4), e002471.
  70. Washburn RL, Cox JE, Muhlestein JB, May HT, Carlquist JF, Le VT, Anderson JL, Horne BD (2019). Pilot Study of Novel Intermittent Fasting Effects on Metabolomic and Trimethylamine N-oxide Changes During 24-hour Water-Only Fasting in the FEELGOOD Trial. Nutrients, 11(2).
  71. Faggioni M, Baber U, Chandrasekhar J, Sartori S, Claessen BE, Rao SV, Vogel B, Effron MB, Poddar K, Farhan S, Kini A, Weintraub W, Toma C, Sorrentino S, Weiss S, Snyder C, Muhlestein JB, Kapadia S, Keller S, Strauss C, Aquino M, Baker B, Defranco A, Pocock S, Henry T, Mehran R (2018). Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. Int J Cardiol, 275, 31-35.
  72. Graves KG, May HT, Jacobs V, Knowlton KU, Muhlestein JB, Lappe DL, Anderson JL, Horne BD, Bunch TJ (2018). CHA(2)DS(2)-VASc scores and Intermountain Mortality Risk Scores for the joint risk stratification of dementia among patients with atrial fibrillation. Heart Rhythm, 16(1), 3-9.
  73. Graves KG, May HT, Knowlton KU, Muhlestein JB, Jacobs V, Lapp DL, Anderson JL, Horne BD, Bunch TJ (2018). Improving CHA(2)DS(2)-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. Open Heart, 5(2), e000907.
  74. Muhlestein JB, May HT, Galenko O, Knowlton KU, Otvos JD, Connelly MA, Lappe DL, Anderson JL (2018). GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study. Am Heart J, 202, 27-32.
  75. Horne BD, Muhlestein JB, Bennett ST, Muhlestein JB, Jensen KR, Marshall D, Bair TL, May HT, Carlquist JF, Hegewald M, Knight S, Le VT, Bunch TJ, Lapp DL, Anderson JL, Knowlton KU (2018). Extreme erythrocyte macrocytic and microcytic percentages are highly predictive of morbidity and mortality. JCI Insight, 3(14).
  76. Graves KG, Muhlestein JB, Lapp DL, McCubrey RO, May HT, Knight S, Le VT, Bair TL, Anderson JL, Horne BD (2018). Practical laboratory-based clinical decision tools and associations with short-term bleeding and mortality outcomes. Clin Chim Acta, 482, 166-171.
  77. Anderson JL, Knowlton KU, May HT, Bair TL, Armstrong SO, Lapp DL, Muhlestein JB (2018). Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study. J Clin Lipidol, 12(4), 1008-1018.e1.
  78. Knight S, Min DB, Le VT, Meredith KG, Dhar R, Biswas S, Jensen KR, Mason SM, Ethington JD, Lappe DL, Muhlestein JB, Anderson JL, Knowlton KU (2018). Implementation of a cardiac PET stress program: comparison of outcomes to the preceding SPECT era. JCI Insight, 3(9).
  79. Foy CG, Lovato LC, Vitolins MZ, Bates JT, Campbell R, Cushman WC, Glasser SP, Gillespie A, Kostis WJ, Krousel-Wood M, Muhlestein JB, Oparil S, Osei K, Pisoni R, Segal MS, Wiggers A, Johnson KC, SPRINT Study Research Group (2018). Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial. J Hypertens, 36(4), 904-915.
  80. Barbagelata A, Bethea CF, Severance HW, Mentz RJ, Albert D, Barsness GW, Le VT, Anderson JL, Bunch TJ, Yanowitz F, Chisum B, Ronnow BS, Muhlestein JB (2017). Smartphone ECG for evaluation of ST-segment elevation myocardial infarction (STEMI): Design of the ST LEUIS International Multicenter Study. J Electrocardiol, 51(2), 260-264.
  81. Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, Lacy M, Marcovina SM, Muhlestein JB, Boden WE (2018). Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol, 12(2), 348-355.e2.
  82. Chandrasekhar J, Baber U, Sartori S, Aquino M, Kini AS, Rao S, Weintraub W, Henry TD, Farhan S, Vogel B, Sorrentino S, Ge Z, Kapadia S, Muhlestein JB, Weiss S, Strauss C, Toma C, DeFranco A, Effron MB, Keller S, Baker BA, Pocock S, Dangas G, Mehran R (2017). Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Can J Cardiol, 34(3), 319-329.
  83. Horne BD, Muhlestein JB, Bhandary D, Hoetzer GL, Khan ND, Bair TL, Lapp DL (2018). Clinically feasible stratification of 1-year to 3-year post-myocardial infarction risk. Open Heart, 5(1), e000723.
  84. Baber U, Chandrasekhar J, Sartori S, Aquino M, Kini AS, Kapadia S, Weintraub W, Muhlestein JB, Vogel B, Faggioni M, Farhan S, Weiss S, Strauss C, Toma C, DeFranco A, Baker BA, Keller S, Effron MB, Henry TD, Rao S, Pocock S, Dangas G, Mehran R (2017). Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv, 10(20), 2017-2025.
  85. May HT, Horne BD, Knight S, Knowlton KU, Bair TL, Lapp DL, Le VT, Muhlestein JB (2017). The association of depression at any time to the risk of death following coronary artery disease diagnosis. Eur Heart J Qual Care Clin Outcomes, 3(4), 296-302.
  86. May HT, Bair TL, Reiss-Brennan B, Knight S, Anderson JL, Horne BD, Brunisholz KD, Muhlestein JB (2017). The association of antidepressant and statin use with death and incident cardiovascular disease varies by depression severity. Psychol Health Med, 22(8), 919-931.
  87. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, SPRINT Research Group (2017). Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. N Engl J Med, 377(8), 733-744.
  88. Baber U, Sartori S, Aquino M, Kini A, Kapadia S, Weiss S, Strauss C, Muhlestein JB, Toma C, Rao SV, DeFranco A, Poddar KL, Chandrasekhar J, Weintraub W, Henry TD, Bansilal S, Baker BA, Marrett E, Keller S, Effron M, Pocock S, Mehran R (2017). Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. Am Heart J, 188, 73-81.
  89. Rozanski A, Muhlestein JB, Berman DS (2016). Primary Prevention of CVD: The Role of Imaging Trials. JACC Cardiovasc Imaging, 10(3), 304-317.
  90. Allen JE, Knight S, McCubrey RO, Bair T, Muhlestein JB, Goldberger JJ, Anderson JL (2016). β-blocker dosage and outcomes after acute coronary syndrome. Am Heart J, 184, 26-36.
  91. May HT, Anderson JL, Muhlestein JB, Lapp DL, Ronnow BS, Horne BD (2015). Improvement in the predictive ability of the Intermountain Mortality Risk Score by adding routinely collected laboratory tests such as albumin, bilirubin, and white cell differential count. Clin Chem Lab Med, 54(10), 1619-28.
  92. May HT, Anderson JL, Winegar DA, Rollo J, Connelly MA, Otvos JD, Muhlestein JB (2016). Utility of high density lipoprotein particle concentration in predicting future major adverse cardiovascular events among patients undergoing angiography. Clin Biochem, 49(15), 1122-1126.
  93. Bunch TJ, May HT, Bair TL, Crandall BG, Cutler MJ, Jacobs V, Mallender C, Muhlestein JB, Osborn JS, Weiss JP, Day JD (2016). Long-term influence of body mass index on cardiovascular events after atrial fibrillation ablation. J Interv Card Electrophysiol, 46(3), 259-65.
  94. Knight S, McCubrey RO, Yuan Z, Woller SC, Horne BD, Bunch TJ, Le VT, Mills RM, Muhlestein JB (2016). Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation. Ther Adv Cardiovasc Dis, 10(4), 231-41.
  95. Muhlestein JB, Lappe DL, Anderson JL, Muhlestein JB, Budge D, May HT, Bennett ST, Bair TL, Horne BD (2015). Both initial red cell distribution width (RDW) and change in RDW during heart failure hospitalization are associated with length of hospital stay and 30-day outcomes. Int J Lab Hematol, 38(3), 328-37.
  96. May HT, Nelson JR, Lirette ST, Kulkarni KR, Anderson JL, Griswold ME, Horne BD, Correa A, Muhlestein JB (2015). The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study. Eur J Prev Cardiol, 23(7), 769-76.
  97. Tamura MK, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C, Jahanian H, Zaharchuk G, SPRINT Study Research Group (2016). Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology, 86(13), 1208-16.
  98. Anderson JL, May HT, Lapp DL, Bair T, Le V, Carlquist JF, Muhlestein JB (2015). Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. Am J Cardiol, 117(5), 794-9.
  99. Pope CA, Muhlestein JB, Anderson JL, Cannon JB, Hales NM, Meredith KG, Le V, Horne BD (2015). Short-Term Exposure to Fine Particulate Matter Air Pollution Is Preferentially Associated With the Risk of ST-Segment Elevation Acute Coronary Events. J Am Heart Assoc, 4(12).
  100. Bunch TJ, May HT, Bair TL, Anderson JL, Crandall BG, Cutler MJ, Jacobs V, Mallender C, Muhlestein JB, Osborn JS, Weiss JP, Day JD (2015). Long-Term Natural History of Adult Wolff-Parkinson-White Syndrome Patients Treated With and Without Catheter Ablation. Circ Arrhythm Electrophysiol, 8(6), 1465-71.
  101. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 373(22), 2103-16.
  102. Horne BD, Hegewald M, Muhlestein JB, May HT, Huggins EJ, Bair TL, Anderson JL (2015). Pulmonary-Specific Intermountain Risk Score Predicts All-Cause Mortality via Spirometry, the Red Cell Distribution Width, and Other Laboratory Parameters. Respir Care, 60(9), 1314-23.
  103. Horne BD, Muhlestein JB, Anderson JL (2015). Health effects of intermittent fasting: hormesis or harm? A systematic review. Am J Clin Nutr, 102(2), 464-70.
  104. Horne BD, Muhlestein JB, Bennett ST, Muhlestein JB, Ronnow BS, May HT, Bair TL, Anderson JL (2015). Association of the dispersion in red blood cell volume with mortality. Eur J Clin Invest, 45(6), 541-9.
  105. Horne BD, Muhlestein JB, Anderson JL (2015). Letter by Horne et al Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Survey III (NHANES-III)". Circulation, 131(19), e472.
  106. Horne BD, Anderson JL, Muhlestein JB, Ridker PM, Paynter NP (2014). Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial. Eur J Prev Cardiol, 22(4), 519-26.
  107. Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn JS, Muhlestein JB, Anderson JL, Mallender C, Bunch TJ (2014). The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm, 12(4), 681-6.
  108. Muhlestein JB, Le V, Albert D, Moreno FL, Anderson JL, Yanowitz F, Vranian RB, Barsness GW, Bethea CF, Severance HW, Ramo B, Pierce J, Barbagelata A, Muhlestein JB (2014). Smartphone ECG for evaluation of STEMI: results of the ST LEUIS Pilot Study. J Electrocardiol, 48(2), 249-59.
  109. Rollo J, Knight S, May HT, Anderson JL, Muhlestein JB, Bunch TJ, Carlquist J (2014). Incidence of dementia in relation to genetic variants at PITX2, ZFHX3, and ApoE ε4 in atrial fibrillation patients. Pacing Clin Electrophysiol, 38(2), 171-7.
  110. Verma DR, Khan MF, Tandar A, Rajasekaran NS, Neuharth R, Patel AN, Muhlestein JB, Badger RS (2015). Nickel elution properties of contemporary interatrial shunt closure devices. J Invasive Cardiol, 27(2), 99-104.
  111. Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, Toth PP, Muhlestein JB, Anderson JL, Knight S, Li Y, Spertus JA, Jones SR, Lipoprotein Investigators Collaborative LIC (2014). HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. Eur Heart J, 36(1), 22-30.
  112. Knight S, Klaskala W, Woller SC, Horne BD, Bunch TJ, Le VT, Mills RM, Muhlestein JB (2015). Antithrombotic therapy in patients with acute coronary syndrome in the intermountain heart collaborative study. Cardiol Res Pract, 2015, 270508.
  113. Rassa AC, Horne BD, McCubrey RO, Bair TL, Muhlestein JB, Morris DR, Anderson JL (2016). Novel Stratification of Mortality Risk by Kidney Disease Stage. Am J Nephrol, 42(6), 443-50.
  114. Muhlestein JB, Lapp DL, Lima JA, Rosen BD, May HT, Knight S, Bluemke DA, Towner SR, Le V, Bair TL, Vavere AL, Anderson JL (2014). Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA, 312(21), 2234-43.
  115. Kwan AC, May HT, Cater G, Sibley CT, Rosen BD, Lima JA, Rodriguez K, Lappe DL, Muhlestein JB, Anderson JL, Bluemke DA (2014). Coronary artery plaque volume and obesity in patients with diabetes: the factor-64 study. Radiology, 272(3), 690-9.
  116. Robison CD, Bair TL, Horne BD, McCubrey RO, Lappe DL, Muhlestein JB, Anderson JL (2014). Hypothyroidism as a risk factor for statin intolerance. J Clin Lipidol, 8(4), 401-7.
  117. Horne BD, Muhlestein JB, Lapp DL, May HT, Carlquist JF, Galenko O, Brunisholz KD, Anderson JL (2012). Randomized cross-over trial of short-term water-only fasting: metabolic and cardiovascular consequences. Nutr Metab Cardiovasc Dis, 23(11), 1050-7.
  118. Burrell LD, Horne BD, Anderson JL, Muhlestein JB, Whisenant BK (2013). Usefulness of left atrial appendage volume as a predictor of embolic stroke in patients with atrial fibrillation. Am J Cardiol, 112(8), 1148-52.
  119. Anderson JL, Knight S, May HT, Horne BD, Bair TL, Huntinghouse JA, Rollo JS, Muhlestein JB, Carlquist JF (2013). Validation and quantification of genetic determinants of lipoprotein-a levels and predictive value for angiographic coronary artery disease. Am J Cardiol, 112(6), 799-804.
  120. Bunch TJ, May HT, Bair TL, Johnson DL, Weiss JP, Crandall BG, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Day JD (2013). Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm, 10(9), 1257-62.
  121. Muhlestein JB, Grehan S (2013). Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina. Drugs R D, 13(3), 207-13.
  122. Harold JG, Bass TA, Bashore TM, Brindis RG, Brush JE Jr, Burke JA, Dehmer GJ, Deychak YA, Jneid H, Jollis JG, Landzberg JS, Levine GN, McClurken JB, Messenger JC, Moussa ID, Muhlestein JB, Pomerantz RM, Sanborn TA, Sivaram CA, White CJ, Williams ES, Presidents and Staff, American College of Cardiology Foundation, American Heart Association, Society of Cardiovascular Angiography and Interventions (2013). ACCF/AHA/SCAI 2013 update of the clinical competence statement on coronary artery interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (writing committee to revise the 2007 clinical competence statement on cardiac interventional procedures). Circulation, 128(4), 436-72.
  123. Horne BD, Lapp DL, Muhlestein JB, May HT, Ronnow BS, Brunisholz KD, Kfoury AG, Bunch TJ, Alharethi R, Budge D, Whisenant BK, Bair TL, Jensen KR, Anderson JL (2013). Repeated measurement of the intermountain risk score enhances prognostication for mortality. PLoS One, 8(7), e69160.
  124. Muhlestein JB (2012). The cardiovascular risk of azithromycin was increased in a large observational cohort study, contradicting findings from prior randomised trials. Evid Based Med, 18(3), e28.
  125. Januzzi JL, Horne BD, Moore SA, Galenko O, Snow GL, Brunisholz KD, Muhlestein JB, Alharethi R, Carlquist JF, Budge D, Rasmussen K, Kfoury AG (2013). Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers, 18(3), 250-6.
  126. May HT, Nelson JR, Kulkarni KR, Anderson JL, Horne BD, Bair TL, Muhlestein JB (2013). A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL₃+IDL]). Lipids Health Dis, 12, 55.
  127. Carlquist JF, Knight S, Horne BD, Huntinghouse JA, Rollo JS, Muhlestein JB, May H, Anderson JL (2013). Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost, 109(4), 744-54.
  128. Bunch TJ, May HT, Crandall BG, Weiss JP, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Johnson DL, Day JD (2012). Intracardiac ultrasound for esophageal anatomic assessment and localization during left atrial ablation for atrial fibrillation. J Cardiovasc Electrophysiol, 24(1), 33-9.
  129. Horne BD, Muhlestein JB, May HT, Carlquist JF, Lapp DL, Bair TL, Anderson JL, Intermountain Heart Collaborative Study Group (2012). Relation of routine, periodic fasting to risk of diabetes mellitus, and coronary artery disease in patients undergoing coronary angiography. Am J Cardiol, 109(11), 1558-62.
  130. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, Robinson M, Barton S, Brunisholz K, Mower CP, Huntinghouse JA, Rollo JS, Siler D, Bair TL, Knight S, Muhlestein JB, Carlquist JF (2012). A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation, 125(16), 1997-2005.
  131. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA, TRA 2PTIMI 50 Steering Committee and Investigators (2012). Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med, 366(15), 1404-13.
  132. Bunch TJ, Mahapatra S, Murdock D, Molden J, Weiss JP, May HT, Bair TL, Mader KM, Crandall BG, Day JD, Osborn JS, Muhlestein JB, Lappe DL, Anderson JL (2011). Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol, 34(12), 1600-6.
  133. Lapp JM, Horne BD, Shah SH, May HT, Muhlestein JB, Lapp DL, Kfoury AG, Carlquist JF, Budge D, Alharethi R, Bair TL, Kraus WE, Anderson JL (2011). Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population. Clin Chim Acta, 412(23-24), 2094-9.
  134. Bunch TJ, Horne BD, Asirvatham SJ, Day JD, Crandall BG, Weiss JP, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Pope CA 3rd (2011). Atrial fibrillation hospitalization is not increased with short-term elevations in exposure to fine particulate air pollution. Pacing Clin Electrophysiol, 34(11), 1475-9.
  135. Horne BD, Muhlestein JB, Lapp DL, Brunisholz KD, May HT, Kfoury AG, Carlquist JF, Alharethi R, Budge D, Whisenant BK, Bunch TJ, Ronnow BS, Rasmusson KD, Bair TL, Jensen KR, Anderson JL (2011). The intermountain risk score predicts incremental age-specific long-term survival and life expectancy. Transl Res, 158(5), 307-14.
  136. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D, Petrie JR, Travers ME, Bouatia-Naji N, Dimas AS, Nica A, Wheeler E, Chen H, Voight BF, Taneera J, Kanoni S, Peden JF, Turrini F, Gustafsson S, Zabena C, Almgren P, Barker DJ, Barnes D, Dennison EM, Eriksson JG, Eriksson P, Eury E, Folkersen L, Fox CS, Frayling TM, Goel A, Gu HF, Horikoshi M, Isomaa B, Jackson AU, Jameson KA, Kajantie E, Kerr-Conte J, Kuulasmaa T, Kuusisto J, Loos RJ, Luan J, Makrilakis K, Manning AK, Martnez-Larrad MT, Narisu N, Nastase Mannila M, Ohrvik J, Osmond C, Pascoe L, Payne F, Sayer AA, Sennblad B, Silveira A, Stanckov A, Stirrups K, Swift AJ, Syvnen AC, Tuomi T, van t Hooft FM, Walker M, Weedon MN, Xie W, Zethelius B, DIAGRAM Consortium, GIANT Consortium, MuTHER Consortium, CARDIoGRAM Consortium, C4D Consortium, Ongen H, Mlarstig A, Hopewell JC, Saleheen D, Chambers J, Parish S, Danesh J, Kooner J, Ostenson CG, Lind L, Cooper CC, Serrano-Ros M, Ferrannini E, Forsen TJ, Clarke R, Franzosi MG, Seedorf U, Watkins H, Froguel P, Johnson P, Deloukas P, Collins FS, Laakso M, Dermitzakis ET, Boehnke M, McCarthy MI, Wareham NJ, Groop L, Pattou F, Gloyn AL, Dedoussis GV, Lyssenko V, Meigs JB, Barroso I, Watanabe RM, Ingelsson E, Langenberg C, Hamsten A, Florez JC (2011). Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes, 60(10), 2624-34.
  137. Bunch TJ, May HT, Bair TL, Crandall BG, Weiss JP, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, Day JD (2011). Trends in early and late mortality in patients undergoing coronary catheterization for myocardial infarction: implications on observation periods and risk factors to determine ICD candidacy. Heart Rhythm, 8(9), 1460-6.
  138. IBC 50K CAD Consortium (2011). Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet, 7(9), e1002260.
  139. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, Day JD (2011). Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol, 22(8), 839-45.
  140. Horne BD, Rasmusson KD, Alharethi R, Budge D, Brunisholz KD, Metz T, Carlquist JF, Connolly JJ, Porter TF, Lapp DL, Muhlestein JB, Silver R, Stehlik J, Park JJ, May HT, Bair TL, Anderson JL, Renlund DG, Kfoury AG (2011). Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet, 4(4), 359-66.
  141. Carlquist JF, McKinney JT, Horne BD, Camp NJ, Cannon-Albright L, Muhlestein JB, Hopkins P, Clarke JL, Mower CP, Park JJ, Nicholas ZP, Huntinghouse JA, Anderson JL (2012). Common Variants in 6 Lipid-Related Genes Discovered by High-Resolution DNA Melting Analysis and Their Association with Plasma Lipids. J Clin Exp Cardiolog, 2(138).
  142. Malasana G, Day JD, Weiss JP, Crandall BG, Bair TL, May HT, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Nelson J, Bunch TJ (2011). A strategy of rapid cardioversion minimizes the significance of early recurrent atrial tachyarrhythmias after ablation for atrial fibrillation. J Cardiovasc Electrophysiol, 22(7), 761-6.
  143. Schunkert H, Knig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Cardiogenics, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Mhleisen TW, Muhlestein JB, Mnzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nthen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schfer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoep JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Mrz W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, ODonnell CJ, McPherson R, Erdmann J, CARDIoGRAM Consortium, Samani NJ (2011). Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet, 43(4), 333-8.
  144. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS, Myocardial Infarction Genetics Consortium, Wellcome Trust Case Control Consortium, Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, Kathiresan S, Samani NJ, Epstein SE, Rader DJ (2011). Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet, 377(9763), 383-92.
  145. Sorensen SG, Aguilar H, McKnight WK, Thomas H, Muhlestein JB (2010). Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices. J Interv Cardiol, 23(6), 575-80.
  146. Horne BD, May HT, Kfoury AG, Renlund DG, Muhlestein JB, Lapp DL, Rasmusson KD, Bunch TJ, Carlquist JF, Bair TL, Jensen KR, Ronnow BS, Anderson JL (2010). The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. Eur J Heart Fail, 12(11), 1203-13.
  147. Carlquist JF, Horne BD, Mower C, Park J, Huntinghouse J, McKinney JT, Muhlestein JB, Anderson JL (2010). An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J Thromb Thrombolysis, 30(3), 358-64.
  148. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, Lapp DL, Muhlestein JB, Intermountain Heart Collaborative IHC Study Group (2010). Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol, 106(7), 963-8.
  149. Muhlestein JB, May HT, Bair TL, Prescott MF, Horne BD, White R, Anderson JL (2010). Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol, 106(6), 764-9.
  150. Anderson JL, Horne BD, Camp NJ, Muhlestein JB, Hopkins PN, Cannon-Albright LA, Mower CP, Park JJ, Clarke JL, Nicholas ZP, McKinney JT, Carlquist JF (2009). Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. Am Heart J, 160(2), 250-256.e3.
  151. May HT, Bair TL, Lapp DL, Anderson JL, Horne BD, Carlquist JF, Muhlestein JB (2010). Association of vitamin D levels with incident depression among a general cardiovascular population. Am Heart J, 159(6), 1037-43.
  152. Sorensen SG, Aguilar H, Reichert W, Goldstein M, Thoen D, Thomas H, Muhlestein JB (2010). Transient neurological symptoms during contrast transcranial Doppler right-to-left shunt testing in patients with cryptogenic neurological disease. J Interv Cardiol, 23(3), 284-90.
  153. Lp-PLA2 Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J (2010). Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 375(9725), 1536-44.
  154. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, Day JD (2009). Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm, 7(4), 433-7.
  155. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL, Lappe DL, Muhlestein JB, Nelson J, Day JD (2009). Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. Pacing Clin Electrophysiol, 33(2), 146-52.
  156. Muhlestein JB (2009). Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost, 103(1), 71-82.
  157. Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, Crandall BG, Osborn JS, Anderson JL, Horne BD, Muhlestein JB, Lappe DL, Moss H, Oliver J, Viau K, Bunch TJ (2010). Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. Cardiology, 116(1), 61-9.
  158. Madsen TE, Pearson RR, Muhlestein JB, Lapp DL, Bair TL, Horne BD, Anderson JL, Intermountain Heart Collaborative IHC Study Group (2009). Risk of nephropathy is not increased by the administration of larger volume of contrast during coronary angiography. Crit Pathw Cardiol, 8(4), 167-71.
  159. Rogers RK, May HT, Anderson JL, Muhlestein JB (2009). Prognostic value of B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure. Am Heart J, 158(5), 777-83.
  160. Horne BD, Carlquist JF, Muhlestein JB, Bair TL, Anderson JL (2009). Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease. Circ Cardiovasc Genet, 1(2), 85-92.
  161. Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, LAllier PL, Pfeffer MA, Aggressive Reduction of Inflammation Stops Events ARISE Trial Investigators (2008). Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet, 371(9626), 1761-8.
  162. Wang SH, Cui HB, Wang DQ, Chen XM, Zhang HK, Cui CC, Chen XY, Liu XH, Zhang Z, Bai F, Jb M (2008). [Geographical characteristics of single nucleotide polymorphism of candidate genes associated with coronary artery disease in Chinese Han population]. Zhonghua Xin Xue Guan Bing Za Zhi, 36(1), 24-9.
  163. Anderson JL, Muhlestein JB (2009). Update of antibiotic trials for secondary prevention of coronary heart disease. Future Cardiol, 1(2), 225-34.
  164. Ronnow BS, Reyna SP, Muhlestein JB, Horne BD, Allen Maycock CA, Bair TL, Carlquist JF, Kfoury AG, Anderson JL, Renlund DG, International Heart Collaborative Study Group (2005). C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. Cardiology, 104(4), 196-201.
  165. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 349(20), 1893-906.
  166. Huang SP, Decker RJ, Goodrich KC, Parker DJ, Muhlestein JB, Blatter DD, Parker DL (1997). Velocity measurement based on bolus tracking with the aid of three-dimensional reconstruction from digital subtraction angiography. Med Phys, 24(5), 677-86.

Review

  1. Muhlestein JB, Moreno FL (2016). Coronary Computed Tomography Angiography for Screening in Patients with Diabetes: Can Enhanced Detection of Subclinical Coronary Atherosclerosis Improve Outcome? [Review]. Curr Atheroscler Rep, 18(11), 64.
  2. Writing Committee Members, Harold JG, Bass TA, Bashore TM, Brindiss RG, Brush JE Jr, Burke JA, Dehmers GJ, Deychak YA, Jneids H, Jolliss JG, Landzberg JS, Levine GN, McClurken JB, Messengers JC, Moussas ID, Muhlestein JB, Pomerantz RM, Sanborn TA, Sivaram CA, Whites CJ, Williamss ES, ACCFAHAACP Task Force On Clinical Competence and Training Members, Halperin JL, Beckman JA, Bolger A, Byrne JG, Lester SJ, Merli GJ, Muhlestein JB, Pina IL, Wang A, Weitz HH (2013). ACCF/AHA/SCAI 2013 Update of the Clinical Competence Statement on Coronary Artery Interventional Procedures: a Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Revise the 2007 Clinical Competence Statement on Cardiac Interventional Procedures). [Review]. Catheter Cardiovasc Interv, 82(2), E69-111.
  3. Harold JG, Bass TA, Bashore TM, Brindis RG, Brush JE Jr, Burke JA, Dehmer GJ, Deychak YA, Jneid H, Jollis JG, Landzberg JS, Levine GN, McClurken JB, Messenger JC, Moussa ID, Muhlestein JB, Pomerantz RM, Sanborn TA, Sivaram CA, White CJ, Williams ES (2013). ACCF/AHA/SCAI 2013 update of the clinical competence statement on coronary artery interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Revise the 2007 Clinical Competence Statement on Cardiac Interventional Procedures). [Review]. J Am Coll Cardiol, 62(4), 357-96.
  4. Muhlestein JB (2009). Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. [Review]. Thromb Haemost, 103(1), 71-82.
  5. Winkelmann BR, Hager J, Kraus WE, Merlini P, Keavney B, Grant PJ, Muhlestein JB, Granger CB (2000). Genetics of coronary heart disease: current knowledge and research principles. [Review]. Am Heart J, 140(4), S11-26.

Case Report

  1. Ning F, Tang M, Wang M, Muhlestein JB, Day JD, Li G, Yan Y (2021). Case Report: Extrinsic Compression of the Left Main Coronary Artery by a Giant Sinus of Valsalva Aneurysm. Front Cardiovasc Med, 8, 753154.

Editorial

  1. Muhlestein JB (2014). QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation. J Electrocardiol, 48(1), 10-1.
  2. Muhlestein JB (2011). Chronic infection and coronary atherosclerosis. Will the hypothesis ever really pan out? J Am Coll Cardiol, 58(19), 2007-9.
  3. Muhlestein JB, Anderson JL (2011). The 9p21.3 genetic region and coronary heart disease where do we go from here? J Am Coll Cardiol, 58(4), 435-7.
  4. Muhlestein JB, Anderson JL (2003). Infectious serology and atherosclerosis: how burdensome is the risk? Circulation, 107(2), 220-2.

Letter

  1. Muhlestein JB, Lappe DL, Anderson JL (2015). Coronary artery disease screening using coronary computed tomography angiography--reply. [Letter to the editor]. JAMA, 313(12), 1267-8.